Abstract:Rationale: Sustained activation of lung fibroblasts and the resulting oversynthesis of the extracellular matrix are detrimental events for patients with interstitial lung diseases (ILDs). Lung biopsy is a primary evaluation technique for the fibrotic status of ILDs, and is also a major risk factor for triggering acute deterioration. Fibroblast activation protein (FAP) is a long-known surface biomarker of activated fibroblasts, but its expression pattern and diagnostic implications in ILDs are poorly defined. Objectives: The present study aims to comprehensively investigate whether the expression intensity of FAP could be used as a potential readout to estimate or measure the amounts of activated fibroblasts in ILD lungs quantitatively. Methods: FAP expression in human primary lung fibroblasts as well as in clinical lung specimens was first tested using multiple experimental methods, including real-time quantitative PCR (qPCR), Western blot, immunofluorescence staining, deep learning measurement of whole slide immunohistochemistry, as well as single-cell sequencing. In addition, FAP-targeted positron emission tomography/computed tomography imaging PET/CT was applied to various types of patients with ILD, and the correlation between the uptake of FAP tracer and pulmonary function parameters was analyzed. Measurements and Main Results: Here, it was revealed, for the first time, FAP expression was upregulated significantly in the early phase of lung fibroblast activation event in response to a low dose of profibrotic cytokine. Single-cell sequencing data further indicate that nearly all FAP-positive cells in ILD lungs were collagen-producing fibroblasts. Immunohistochemical analysis validated that FAP expression level was closely correlated with the abundance of fibroblastic foci on human lung biopsy sections from patients with ILDs. We found that the total standard uptake value (SUV) of FAP inhibitor (FAPI) PET (SUVtotal) was significantly related to lung function decline in patients with ILD. Conclusions: Our results strongly support that in vitro and in vivo detection of FAP can assess the profibrotic activity of ILDs, which may aid in early diagnosis and the selection of an appropriate therapeutic window.

Immune mechanisms in fibrotic interstitial lung disease

Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis?

Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease

Exploring the Interplay between Cellular Senescence, Immunity, and Fibrosing Interstitial Lung Diseases: Challenges and Opportunities

Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases

The Immunomodulatory Role of Interleukin-35 in Fibrotic Diseases

The dawn of precision medicine in fibrotic interstitial lung disease

Progression of fibrosing interstitial lung disease

Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players

Current Challenges and Novel Therapeutic Perspectives

Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease

Fibrosing interstitial lung diseases: knowns and unknowns

Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)

Emerging role of immune cells as drivers of pulmonary fibrosis

Cell-Based Therapy for Fibrosing Interstitial Lung Diseases, Current Status, and Potential Applications of iPSC-Derived Cells

Role of Immune Cells in the Initiation and Progression of Pulmonary Fibrosis

Innate Lymphoid Cells: A Promising New Regulator In Fibrotic Diseases

Comprehensive Analysis of Fibroblast Activation Protein Expression in Interstitial Lung Diseases

The role of immune response in the pathogenesis of idiopathic pulmonary fibrosis: far beyond the Th1/Th2 imbalance

The evolving pharmacotherapy of pulmonary fibrosis